Vical Receives $2.3 Million Payment for Continued Funding of Phase III Trial

Vical Incorporated announced the receipt of a $2.3 million cash payment from AnGes MG, Inc., related to continued progress in the company’s ongoing Allovectin-7 Phase 3 metastatic melanoma trial.
Fox Business